Euroscreen and Medarex Announce License and Research Service Agreement

27-Jun-2006

Medarex, Inc. and Euroscreen announced the completion of a license and research agreement for the exclusive worldwide development and commercialization of antibody-based products against certain targets for various diseases, including inflammatory and autoimmune conditions. Medarex intends to use its UltiMAb(R) technology to create antibodies to targets provided by Euroscreen.

Under the terms of the agreement, Euroscreen has granted Medarex exclusive rights to develop and commercialize antibody products against two undisclosed targets. Euroscreen will receive an upfront payment and may receive milestone payments and royalties on any future sales of products developed and commercialized by Medarex. Medarex and Euroscreen reserve the right to collaborate on certain preclinical activities in support of the development of such products. Financial details of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances